{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T05:30:27Z","timestamp":1777613427103,"version":"3.51.4"},"reference-count":21,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,7,17]],"date-time":"2025-07-17T00:00:00Z","timestamp":1752710400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:p>Secukinumab, a monoclonal antibody targeting interleukin-17A, is effective for treating moderate-to-severe plaque psoriasis but may induce paradoxical inflammatory bowel disease, particularly Crohn\u2019s disease. We describe a 41-year-old male with a history of psoriasis who developed new-onset Crohn\u2019s disease accompanied by a perianal abscess after prolonged secukinumab treatment. The patient experienced increased bowel movements and postoperative fever, and colonoscopy revealed diffuse colonic inflammation and deep ulcerations; histopathology confirmed chronic active enteritis with epithelioid granulomas. Infectious causes and other differential diagnoses were excluded. Treatment with corticosteroids and mesalamine led to symptom resolution and normalization of inflammatory markers. This case illustrates a rare but important adverse effect of IL-17A inhibition and emphasizes the dual role of IL-17A in promoting skin inflammation while maintaining intestinal homeostasis. Careful evaluation of gastrointestinal history and close monitoring during therapy are essential to prevent and manage potential intestinal complications.<\/jats:p>","DOI":"10.3389\/fimmu.2025.1628461","type":"journal-article","created":{"date-parts":[[2025,7,17]],"date-time":"2025-07-17T05:25:33Z","timestamp":1752729933000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":5,"title":["Secukinumab-induced Crohn\u2019s disease in a psoriasis patient: a case report highlighting paradoxical reactions to IL-17 inhibition"],"prefix":"10.3389","volume":"16","author":[{"given":"Huiling","family":"Dai","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chenyi","family":"Xu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yehuang","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kunlan","family":"Wu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yang","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hao","family":"Ge","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yanlan","family":"Wu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2025,7,17]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"573","DOI":"10.35541\/cjd.20220839","article-title":"Chinese psoriasis diagnosis and treatment guidelines (2023 edition)","volume":"56","year":"2023","journal-title":"Chin J Dermatol"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.3969\/j.issn.1006-4931.2021.23.034","article-title":"Progress of interleukin 17 monoclonal antibody in the treatment of psoriatic arthritis","volume":"30","author":"Hou","year":"2021","journal-title":"Chin Pharm Industry"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1038\/ni0609-568","article-title":"IL-17A directly inhibits TH1 cells and thereby suppresses development of intestinal inflammation","volume":"10","author":"Awasthi","year":"2009","journal-title":"Nat Immunol"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1136\/gutjnl-2012-304154","article-title":"Secukinumab failure in Crohn's disease: the yeast connection","volume":"62","author":"Colombel","year":"2013","journal-title":"Gut"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1038\/ajg.2016.298","article-title":"A randomized, double-blind, pla-cebo-controlled phase 2 study of brodalumab in patients with moderate-t-o-severe crohn\u2019s disease","volume":"111","author":"Targan","year":"2016","journal-title":"Am J Gastroenterol"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2020-217927","article-title":"Paradoxical gastrointestinal effects of interleukin-17 blockers","volume":"79","author":"Fauny","year":"2020","journal-title":"Ann Rheumatic Dis"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.3969\/j.issn.1674-8468.2023.04.012","article-title":"Adverse effects and coping strategies of biologic therapy for psoriasis","volume":"30","author":"Yang","year":"2023","journal-title":"J Dermatol Venereology"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2020.12.010","article-title":"Paradoxical eruptions to targeted therapies in dermatology: a systematic review and analysis","volume":"86","author":"Murphy","year":"2020","journal-title":"J Am Acad Dermatol"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.3969\/j.issn.1006-4931.2025.01.025","article-title":"Case reports and literat\u2013ure analysis of inflammatory bowel disease caused by stavudine","volume":"34","author":"Yang","year":"2025","journal-title":"China Pharm Industry"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.3760\/cma.j.cn114015-20211210-01248","article-title":"Ulcerative colitis associated with sterculizumab injection","volume":"24","author":"Ma","year":"2022","journal-title":"J Adverse Drug Reactions"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1093\/ecco-jcc\/jjy063","article-title":"Emergence of inflammatory bowel disease during treatment with secukinumab","volume":"12","author":"Fobelo Lozano","year":"2018","journal-title":"J Crohns Colitis"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1111\/jop.12910","article-title":"A review and guide to drug-associated oral adverse effects-Oral mucosal and lichenoid reactions Part 2","volume":"48","author":"Teoh","year":"2019","journal-title":"J Oral Pathol Med"},{"key":"B13","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1016\/j.autrev.2013.06.004","article-title":"Innate and adaptive immunity in inflammatory bowel disease","volume":"13","author":"Geremia","year":"2014","journal-title":"Autoimmun Rev"},{"key":"B14","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1159\/000500116","article-title":"Psoriasis and inflammatory bowel disease","volume":"37","author":"Cottone","year":"2019","journal-title":"Digestive Dis"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1155\/2013\/983902","article-title":"Correlations between psoriasis and inflammatory bowel diseases","volume":"2013","author":"Skroza","year":"2013","journal-title":"BioMed Res Int"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.14528","article-title":"Association between psoriasis and inflammatory bowel disease: a Danish nationwide cohort study","volume":"175","author":"Egeberg","year":"2016","journal-title":"Br J Dermatol"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(18)31713-6","article-title":"Efficacy and safety of risankizumab in moderate-to-severe plaque psoriasis (UltIMMa-1 and UltIMMa-2): results from two double-blind, randomised, placebo-controlled and ustekinumab-controlled phase 3 trials","volume":"392","author":"Gordon","year":"2018","journal-title":"Lancet"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.2340\/actadv.v101.283","article-title":"Real-life effectiveness and safety of risankizumab in moderate-to-severe plaque psoriasis: A 40-week multicentric retrospective study","volume":"101","author":"Borroni","year":"2021","journal-title":"Acta Derm Venereol"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1007\/s13555-022-00726-w","article-title":"Safety of biologic therapies in patients with moderate-to-severe plaque psoriasis and concomitant viral hepatitis: A monocentric retrospective study","volume":"12","author":"Gargiulo","year":"2022","journal-title":"Dermatol Ther (Heidelb)"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1001\/jamadermatol.2015.0718","article-title":"Risk of serious infection with biologic and systemic treatment of psoriasis: results from the psoriasis longitudinal assessment and registry (PSOLAR)","volume":"151","author":"Kalb","year":"2015","journal-title":"JAMA Dermatol"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2017.03.021","article-title":"EASL 2017 Clinical Practice Guidelines on the management of hepatitis B virus infection","volume":"67","author":"Ofliver","year":"2017","journal-title":"J Hepatol"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2025.1628461\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,7,17]],"date-time":"2025-07-17T05:25:36Z","timestamp":1752729936000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2025.1628461\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,17]]},"references-count":21,"alternative-id":["10.3389\/fimmu.2025.1628461"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2025.1628461","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,7,17]]},"article-number":"1628461"}}